[go: up one dir, main page]

GB202215142D0 - Novel cell lines and their use in therapy - Google Patents

Novel cell lines and their use in therapy

Info

Publication number
GB202215142D0
GB202215142D0 GBGB2215142.7A GB202215142A GB202215142D0 GB 202215142 D0 GB202215142 D0 GB 202215142D0 GB 202215142 A GB202215142 A GB 202215142A GB 202215142 D0 GB202215142 D0 GB 202215142D0
Authority
GB
United Kingdom
Prior art keywords
therapy
cell lines
novel cell
novel
lines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2215142.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of York
Original Assignee
University of York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of York filed Critical University of York
Priority to GBGB2215142.7A priority Critical patent/GB202215142D0/en
Publication of GB202215142D0 publication Critical patent/GB202215142D0/en
Priority to KR1020257015537A priority patent/KR20250084967A/en
Priority to CN202380084719.5A priority patent/CN120435547A/en
Priority to JP2025521029A priority patent/JP2025535110A/en
Priority to EP23797845.7A priority patent/EP4602151A1/en
Priority to PCT/GB2023/052658 priority patent/WO2024079477A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
GBGB2215142.7A 2022-10-13 2022-10-13 Novel cell lines and their use in therapy Ceased GB202215142D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB2215142.7A GB202215142D0 (en) 2022-10-13 2022-10-13 Novel cell lines and their use in therapy
KR1020257015537A KR20250084967A (en) 2022-10-13 2023-10-13 Novel cell lines and their use in therapy
CN202380084719.5A CN120435547A (en) 2022-10-13 2023-10-13 Novel cell lines and their therapeutic applications
JP2025521029A JP2025535110A (en) 2022-10-13 2023-10-13 Novel cell lines and their use in therapy
EP23797845.7A EP4602151A1 (en) 2022-10-13 2023-10-13 Novel cell lines and their use in therapy
PCT/GB2023/052658 WO2024079477A1 (en) 2022-10-13 2023-10-13 Novel cell lines and their use in therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2215142.7A GB202215142D0 (en) 2022-10-13 2022-10-13 Novel cell lines and their use in therapy

Publications (1)

Publication Number Publication Date
GB202215142D0 true GB202215142D0 (en) 2022-11-30

Family

ID=84818420

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2215142.7A Ceased GB202215142D0 (en) 2022-10-13 2022-10-13 Novel cell lines and their use in therapy

Country Status (6)

Country Link
EP (1) EP4602151A1 (en)
JP (1) JP2025535110A (en)
KR (1) KR20250084967A (en)
CN (1) CN120435547A (en)
GB (1) GB202215142D0 (en)
WO (1) WO2024079477A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2054506A1 (en) * 2006-08-15 2009-05-06 Agency for Science, Technology and Research Mesenchymal stem cell conditioned medium
CN102014934B (en) * 2008-02-22 2014-08-20 新加坡科技研究局 Mesenchymal stem cell particles
WO2021198927A1 (en) * 2020-03-30 2021-10-07 Universidade Do Minho Compositions for therapy or treatment of parkinson's disease, methods and uses thereof

Also Published As

Publication number Publication date
EP4602151A1 (en) 2025-08-20
JP2025535110A (en) 2025-10-22
WO2024079477A1 (en) 2024-04-18
KR20250084967A (en) 2025-06-11
CN120435547A (en) 2025-08-05

Similar Documents

Publication Publication Date Title
GB2611448B (en) Polypeptide useful in adoptive cell therapy
GB2610308B (en) Improvements in and relating to cell configuration and control
GB202014736D0 (en) Novel compounds and their use in therapy
GB202215142D0 (en) Novel cell lines and their use in therapy
IL319234A (en) Pyrazolylsulfonamide compounds and their use in therapy
GB202215141D0 (en) Novel cell line and its use in therapy
EP4185757A4 (en) Improvements in and relating to mobile medical units
EP4228710A4 (en) Therapeutic radiolabelled conjugates and their use in therapy
IL309249A (en) Conjugates comprising phosphoantigens and their use in therapy
GB202305546D0 (en) Novel compounds and their use in therapy
GB202305541D0 (en) Novel compounds and their use in therapy
GB202403391D0 (en) Novel compounds and their use in therapy
GB202417085D0 (en) Electrolutic cells and their use
GB202110932D0 (en) Novel compounds and their use in therapy
PT4284843T (en) Novel sialosides and their use in therapy
GB202011808D0 (en) Novel compounds and their use in therapy
IL304496A (en) T cells for use in therapy
GB202104353D0 (en) Improvements in and relating to connections
HK40099063A (en) Novel sialosides and their use in therapy
GB2581035B (en) Novel compounds and their use in therapy
AU2022900994A0 (en) Conjugates and their use in therapy
CA3287178A1 (en) Novel mettl3 inhibitors and use thereof in therapy
AU2024244637A1 (en) Novel mettl3 inhibitors and use thereof in therapy
GB2625510B (en) Improvements in and relating to data centre construction
GB202316080D0 (en) Improvements in or relating to devices and methods

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)